Advicenne Cash Flow Conversion Efficiency
Advicenne cash flow conversion efficiency. Based on the latest financial reports, Advicenne (ALDVI) has a cash flow conversion efficiency ratio of -0.099x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.89 Million ≈ $2.20 Million USD) by net assets (€-19.07 Million ≈ $-22.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Advicenne (2015–2024)
Cash flow conversion efficiency of Advicenne from 2015 to 2024. This chart illustrates how Advicenne's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALDVI stock price and chart for real-time trading data and today's change.
Advicenne Cash Flow Conversion Ratio Explained
Advicenne cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Advicenne Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Advicenne ranked by their cash flow conversion efficiency. Also see market value of Advicenne for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mitra Pemuda Tbk PT
JK:MTRA
|
-0.004x |
|
Plasticos Compuestos S.A.
MC:KOM
|
-0.013x |
|
Natuzzi SpA
NYSE:NTZ
|
0.037x |
|
Immolease Trust NV
BR:DIEG
|
N/A |
|
Daewoo SBI SPAC 1
KQ:215480
|
0.196x |
|
Genomtec S.A.
WAR:GMT
|
-0.262x |
|
Cosmos Yatirim Holding AS
IS:COSMO
|
0.048x |
|
Vistry Group PLC
LSE:VTY
|
0.059x |
Annual Cash Flow Conversion Efficiency for Advicenne (2015–2024)
The table below shows the annual cash flow conversion efficiency of Advicenne from 2015 to 2024. Review Advicenne (ALDVI) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-19.07 Million ≈ $-22.30 Million |
€-762.00K ≈ $-890.86K |
0.040x | -92.01% |
| 2023-12-31 | €-11.97 Million ≈ $-13.99 Million |
€-5.99 Million ≈ $-7.00 Million |
0.500x | -41.93% |
| 2022-12-31 | €-10.62 Million ≈ $-12.41 Million |
€-9.15 Million ≈ $-10.69 Million |
0.862x | +102.13% |
| 2021-12-31 | €309.00K ≈ $361.25K |
€-12.53 Million ≈ $-14.64 Million |
-40.534x | -1034.15% |
| 2020-12-31 | €3.27 Million ≈ $3.83 Million |
€-11.69 Million ≈ $-13.67 Million |
-3.574x | -538.39% |
| 2019-12-31 | €16.92 Million ≈ $19.79 Million |
€-9.47 Million ≈ $-11.08 Million |
-0.560x | -62.93% |
| 2018-12-31 | €29.63 Million ≈ $34.64 Million |
€-10.18 Million ≈ $-11.90 Million |
-0.344x | -98.49% |
| 2017-12-31 | €33.51 Million ≈ $39.18 Million |
€-5.80 Million ≈ $-6.78 Million |
-0.173x | -1230.87% |
| 2016-12-31 | €-5.15 Million ≈ $-6.02 Million |
€67.00K ≈ $78.33K |
-0.013x | -100.81% |
| 2015-12-31 | €-1.67 Million ≈ $-1.95 Million |
€-2.69 Million ≈ $-3.15 Million |
1.613x | -- |
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more